Pathologist Pathway

Learn from the leaders of the DPA, ESDIP and JSDA as they share their expertise on why now is the time to support a digital transformation in pathology.

The widespread use of digital images enables new opportunities for AI driven research, allowing for the possibility of new discoveries and automation of routine diagnostic tasks. What are the ethical consequences of these changes?

Curious about what the future holds? Listen to our global panel of expert pathologists and learn more about AI, digital pathology, and how future innovations may lead the way.

Thinking about starting your digital journey? Watch this panel discussion and learn from leaders of the digital pathology associations in Europe (ESDIP), United States (DPA) and Japan (JDPA) on the future of pathology.

Digital imaging in medicine has come a long way with numerous technology advances and global adoption in many clinical care settings. Digital imaging in Anatomic Pathology has also advanced significantly but remains among the last of the medical fields to undergo a complete digital transformation.

To bring digital into daily practice we need rigor and transparency as to how we recoup the investment in digital pathology, and this requires defining ROI with confidence and specificity.

An integrated digital pathology ecosystem is only possible to maintain in the long term when international interoperability standards are followed. It must be envisioned as a global strategy comprising not only imaging data.

The augmented pathologist works synergistically with AI, has no fear of being substituted and has the pride of being part of an empowered generation that envisions better care for our patients.

Current technology allows tumors to be painted with multiple colors, termed multiplex staining. Multiplex staining today used in research, may also assist with cancer diagnoses clinically via: preservation of tissue, improved diagnostic accuracy, and enhanced diagnostic insight.

Molecular pathology has the potential to create health service efficiencies and improve outcomes for cancer patients, we just have to imagine a world in which molecular pathology & personalised medicine is the norm – then create it, says Dr. Matthew Clarke.